|
NEWSLETTER
November, 2016
|
 |
 |
 |
 |
|
|
|
| |
|
SYNTHETIC BIOLOGY: FROM IDEAS TO MARKET |
|
|
|
In line with Genopole's strategy on synthetic biology, which began with the development of a dedicated Master's degree in 2008 at the University of Evry (mSSB) followed by the creation of the ISSB in 2010, the biocluster is organizing its first meeting on the economics of synthetic biology. With less than a month to go before the colloquium on December 6th, Genopole is excited to announce the programme of the colloquium which is organised around two main themes – the initial steps in the industrialisation of synthetic biology and the economics involved on a wider scale.
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
| |
FRENCH COMPETITIVENESS |
|
| |
|
 Capitals invested in tech in Europe
(in millions of dollars).
Source: Les Echos dated November 11, 2016
|
French Attractiveness Focus - Tech Capital Investment In France Just About To Catch Up With The UK
France is already known for its engineering and scientific talent as well as for its creativity.
This country could soon be taking over the UK for the title of European capital of tech start-ups.
According to the latest figures published by CB Insights for Q3-2016, France is just about to catch up with the UK for tech capital investment and is well ahead of Germany (see comparative figures for the last quarters in France, the UK and Germany).
In Q3-2016, France compared most favourably with the UK, with 857M US$ invested in French tech, a figure that is just short by 7% of the UK investments at 919M US$. |
|
|
|
| |
|
Whilst UK tech investment is possibly impacted by Brexit-related uncertainty, France has experienced a real explosion of investments in Q3-2016 as compared to the same period in 2015. It is 145 companies that have been financed during this summer quarter as compared to 59 on average per quarter since 2012.
France’s venture capital ecosystem and the country’s innovation support measures have improved significantly over the last few years with the Banque Public d’Investissement playing a key role in leading this change of tech fortune in the Hexagone.
|
|
|
|
|
|
|
|
|
|
|
|
|
REAL ESTATE |
|
|
|
On October 1st of last year, Genopole and the SEM Genopole inaugurated a new real estate offering dedicated to biotech companies.
Halfway between the incubator for start-ups, and services offices consisting in bare spaces for mature companies to rearrange, the B7 provides an intermediate offer.
Many new companies have set up in the building but there are still a few spaces available so if you are interested, do get in touch with our dedicated team specialised in accompaniment and financing (Laurent.pepin@genopole.fr).
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
NEWS FROM THE COMPANIES |
|
|
|
|
Theraclion Raises €9.6 Million
Theraclion, which specialises in high-tech medical equipment using high-intensity focused ultrasound (HIFU), has successfully conducted a capital increase with preferential subscription rights which took place from 26 July to 5 August 2016. This has raised a total gross amount of €9,629,337 through the issue of 1,610,257 new shares at a price of 5.98 euros. |
|
|
|
|
|
|
|
|
 |
Pharnext Raises € 31 million on Euronext Alternext Stock Exchange Paris
On 27 October, Pharnext SA which develops an advanced portfolio of products in the field of neurodegenerative diseases, announced the publication of its financial and operational results for the six months to 30 June 2016.
|
|
|
|
|
"Our IPO in July enabled us to raise €31 million on Euronext Alternext Stock Exchange Paris and to advance our two PLÉOMÉDICAMENT® currently in clinical development process. We were therefore able to continue the recruitment of patients for the international Phase 3 trial of PXT3003, in the treatment of CMT 1A, and the analysis of the results of the Phase 2a trial of PXT864 in the treatment of Alzheimer’s disease. The IPO also enabled us to strengthen Pharnext’s financial structure" noted Daniel Cohen, CEO and founder of Pharnext. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EVENTS |
|
| |
|
Bernard Barataud Awarded Honorary Professorship in Evry, the French Cradle Of Human Genomics
2016 marks the 30th anniversary of the Telethon, the 20th anniversary of the publication of the first Human Genome Map and of the creation of the Genoscope, as well as the 10th anniversary of whole human genome sequencing. |
|
|
 |
|
|
|
As such, on November 4th, Bernard Barataud was awarded an honorary professorship from the University of Evry in recognition for his accomplishments in the fight against neuromuscular diseases. Present at the ceremony were Manuel Valls, the French Prime Minister, Thierry Mandon, Minister of State for Higher Education and Research, Marianne Duranton, President of Genopole, and Pierre Tambourin, CEO of Genopole.
Along with Pierre Birambeau, Bernard Barataud was the creator of the French Telethon as well as the father of medical genomics in France. Thanks to his visionary spirit, he was at its onset with the creation of the Genethon laboratory in 1990.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NETWORKING |
|
|
|
 |
Genopole in Korea
Genopole was represented by Drs. Francis Quétier and Denis Gauvreau at the 2016 Korea-Forum 3rd Joint Forum on Innovative Industry held in Seoul on October 26, 2016. The Forum was co-hosted by the Ministry of Trade, Industry and Energy of Korea and the Ministry of Economy and Finance of France. |
|
|
|
|
|
Dr. Gauvreau was a speaker at the session on Progress and Achievements of Korea-France Cooperation where he reviewed the objectives and developments of the Strategic Exploratory Agreement (SEA) signed in June 2016 between Genopole and the Korean bioclusters KBIO and DGMIF.
|
|
|
|
|
|
|
|
|
Come and Meet Genopole Entreprises at Biofit
Come and meet our Genopole Entreprises team at Biofit in Lille. For its 5th edition, Biofit will bring together over 1,300 international participants from more than 30 countries. |
 |
|
|
|
|
|
Including pharma, biotech, in vitro diagnostic companies, R&D services, but also technology transfer professionals, academics and investors, who will meet on November 30th and December 1st 2016 in Lille to:
>>
engage in new partnerships
>>
encourage the development of public / private projects
>>
intensify licenses stream |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
AND ALSO |
|
| |
|
 |
The Young Biotech Award – The Final Steps
Throughout the day on 17 November, Genopole held “The Entrepreneur Path”– a key event in the Young Biotech Award to select finalists to the competition.
Working on the principle of speed-dating, only in this case speed-meeting, the 9 candidates initially selected had 25 minutes to pitch and convince their audience that they deserved a spot in the final.
Genopole had invited all major players of business creation and innovation: TTOs, investors, industrials… to evaluate the various projects.
|
|
|
At the end of day, whether or not they were selected, all the candidates received crucial feedback to help them further develop their projects. This year’s edition was marked by projects with a high societal impact – environmentally-friendly solutions, highly nutritious foods, and a more sustainable agriculture.
We cannot wait to introduce you to the next laureates in our December edition!
|
|
|
|
|
|
|
|
|
|
|
|
|
